• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.

作者信息

Reeves Brandi N, Masarova Lucia, Abu-Zeinah Ghaith, Hunter Anthony M, Shatzel Joseph J, Qin Albert, Yoon Chang Ho, Cai Ling-Yu, Wei Yu-Feng, Mesa Ruben A

机构信息

Division of Hematology, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Ann Hematol. 2025 Jul 10. doi: 10.1007/s00277-025-06480-1.

DOI:10.1007/s00277-025-06480-1
PMID:40637862
Abstract
摘要

相似文献

1
A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.一项利用美国食品药品监督管理局不良事件报告系统（FAERS）数据库对真性红细胞增多症治疗相关不良事件进行的药物警戒研究。
Ann Hematol. 2025 Jul 10. doi: 10.1007/s00277-025-06480-1.
2
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.基于 FDA 不良事件报告系统数据库的真实世界研究：抗肥胖药物与消化道不良事件关联性的分层分析。
BMC Pharmacol Toxicol. 2024 Sep 12;25(1):64. doi: 10.1186/s40360-024-00789-9.
3
A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database.一项基于FAERS数据库的赛妥珠单抗聚乙二醇化修饰物的真实世界药物警戒研究。
Sci Rep. 2025 Aug 5;15(1):28529. doi: 10.1038/s41598-025-13502-5.
4
Comparative Analysis of Adverse Events Linked to PEG-rhG-CSF and rhG-CSF in Real-World Settings: Disproportionate Examination of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database.真实世界中与聚乙二醇化重组人粒细胞集落刺激因子（PEG-rhG-CSF）和重组人粒细胞集落刺激因子（rhG-CSF）相关不良事件的比较分析：对美国食品药品监督管理局（FDA）不良事件报告系统（FAERS）数据库的不均衡审查
Clin Ther. 2025 Aug;47(8):624-630. doi: 10.1016/j.clinthera.2025.04.017. Epub 2025 May 22.
5
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.免疫检查点抑制剂在非小细胞肺癌中的不良反应：临床试验和 FDA 药物警戒系统的安全性分析。
Front Immunol. 2024 Apr 30;15:1396752. doi: 10.3389/fimmu.2024.1396752. eCollection 2024.
6
Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.血栓栓塞事件与血小板生成素受体激动剂之间的关系：对美国食品药品监督管理局不良事件报告系统和日本药品不良反应报告的药物警戒分析
BMJ Open. 2025 Aug 10;15(8):e099153. doi: 10.1136/bmjopen-2025-099153.
7
Safety profile of ramelteon from the perspective of physicians and pharmacists: a 20-year real-world pharmacovigilance analysis based on the FAERS database.从医生和药剂师角度看雷美替胺的安全性：基于FAERS数据库的20年真实世界药物警戒分析
BMC Psychiatry. 2025 Jul 7;25(1):683. doi: 10.1186/s12888-025-07127-1.
8
A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system.一项基于美国食品药品监督管理局不良事件报告系统数据的伏硫西汀药物警戒研究。
Sci Rep. 2025 Aug 7;15(1):28886. doi: 10.1038/s41598-025-13786-7.
9
Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.镥[177Lu]奥曲肽（Lutathera）的上市后安全性评估：FDA不良事件报告系统的药物警戒分析
Clin Nucl Med. 2025 Aug 1;50(8):714-720. doi: 10.1097/RLU.0000000000005861. Epub 2025 Apr 30.
10
Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system.妊娠期间与阿达木单抗、依那西普、乌司奴单抗和度普利尤单抗相关的流产不良事件：一项基于美国食品药品监督管理局不良事件报告系统的药物警戒研究。
Drug Discov Ther. 2025 Jul 4;19(3):160-173. doi: 10.5582/ddt.2025.01043. Epub 2025 Jun 29.

本文引用的文献

1
Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.真性红细胞增多症患者接受聚乙二醇干扰素α-2b治疗的血液学和分子学反应：一项前瞻性研究的48周结果
Int J Cancer. 2025 Aug 1;157(3):526-533. doi: 10.1002/ijc.35411. Epub 2025 Mar 15.
2
Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia.聚乙二醇干扰素α-2b具有抗真性红细胞增多症活性，且不会引起具有临床意义的贫血。
BJC Rep. 2024 Jul 11;2(1):51. doi: 10.1038/s44276-024-00076-4.
3
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.
在真性红细胞增多症患者接受聚乙二醇干扰素α-2b治疗过程中，分子学缓解与完全血液学缓解未同时出现。
Br J Haematol. 2024 Dec;205(6):2510-2514. doi: 10.1111/bjh.19846. Epub 2024 Oct 27.
4
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.聚乙二醇干扰素α-2b治疗真性红细胞增多症的药代动力学、疗效和安全性的种族敏感性分析。
Front Pharmacol. 2024 Sep 24;15:1455979. doi: 10.3389/fphar.2024.1455979. eCollection 2024.
5
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.用聚乙二醇干扰素α-2b治疗有效管理真性红细胞增多症
J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9.
6
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。
Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.
7
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.罗特西普干扰素与标准疗法治疗低危真性红细胞增多症患者的比较。
NEJM Evid. 2023 Jun;2(6):EVIDoa2200335. doi: 10.1056/EVIDoa2200335. Epub 2023 May 15.
8
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.聚乙二醇干扰素治疗低危真性红细胞增多症的2期随机研究：5年药物生存情况及疗效结果
Ann Hematol. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9. Epub 2023 Dec 7.
9
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.接受罗培戈干扰素α-2b治疗与最佳可用治疗的真性红细胞增多症患者的无事件生存期
Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26.
10
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好：一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.